Choose which categories of cookies you allow. Strictly necessary cookies are always on.
Required for core site functionality, security and your session. Always active.
Help us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
Used to measure campaigns and show you relevant ads on other sites (e.g. LinkedIn, Google Ads).
Respiratory Devices Market Analysis size 2021 was recorded $21738.9 Million whereas by the end of 2026 it will reach $28710.21 Million. According to the author, by 2033 Respiratory Devices market size will become $42376.3. Respiratory Devices market will be growing at a CAGR of 5.72% during 2026 to 2033. Download a free sample with data verified by Supriya Yadav
| Data Timeline | Historical Data: 2022–2025 | Base Year: 2025 | Forecast Period: 2026–2034 |
|---|---|
| Type Segment | Invasive, Non invasive |
| Application Segment | Hospitals/Clinics, Household, Other (In army Outer space etc.) |
| Product Segment | Therapeutic Devices, Drug Delivery Devices, Mechanical Ventilators, Continuous Positive Airway Pressure, Resuscitators, Humidifiers, Airway Clearance Devices, Oxygen Concentrators, Consumables & Disposables, Others |
|---|---|
| Indication Segment | Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, Others |
| Conclusion Segment | The global respiratory device market is at a pivotal juncture, shaped by rising chronic respiratory conditions, aging populations, and the growing demand for home-based care. There is a significant shift toward smart, connected devices that enable remote monitoring and early intervention, driven by AI, IoT, and wearable tech integration. Post-pandemic resilience has also spurred regulatory agility and faster adoption cycles. Companies investing in user-friendly designs, digital health ecosystems, and value-based care models are best positioned to lead. Emerging markets, with unmet needs and rising healthcare access, offer untapped growth, making localization strategies and cost-effective innovation critical for sustained success. |
| Regions & Countries |
|
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | $ 21738.9 Million | $ 27156 Million | $ 42376.3 Million | 5.72% |
| North America | $ 8608.6 Million | $ 10455.1 Million | $ 15340.2 Million | 4.909% |
| United States | $ 6645.84 Million | $ 7977.21 Million | $ 11428.5 Million | 4.596% |
| Canada | $ 1394.59 Million | $ 1735.54 Million | $ 2653.86 Million | 5.452% |
| Mexico | $ 568.17 Million | $ 742.31 Million | $ 1257.9 Million | 6.815% |
| Europe | $ 5891.24 Million | $ 7277.81 Million | $ 11017.8 Million | 5.32% |
| United Kingdom | $ 1060.42 Million | $ 1273.62 Million | $ 1795.91 Million | 4.389% |
| France | $ 830.66 Million | $ 1004.34 Million | $ 1399.27 Million | 4.232% |
| Germany | $ 1184.14 Million | $ 1433.73 Million | $ 2071.35 Million | 4.706% |
| Italy | $ 565.56 Million | $ 698.67 Million | $ 1024.66 Million | 4.903% |
| Russia | $ 447.73 Million | $ 560.39 Million | $ 870.41 Million | 5.658% |
| Spain | $ 412.39 Million | $ 538.56 Million | $ 914.48 Million | 6.842% |
| Sweden | $ 312.24 Million | $ 378.45 Million | $ 561.91 Million | 5.065% |
| Denmark | $ 329.91 Million | $ 436.67 Million | $ 760.23 Million | 7.176% |
| Switzerland | $ 229.76 Million | $ 298.39 Million | $ 506.82 Million | 6.846% |
| Luxembourg | $ 135.5 Million | $ 160.11 Million | $ 231.38 Million | 4.71% |
| Rest of Europe | $ 382.93 Million | $ 494.89 Million | $ 881.43 Million | 7.482% |
| Asia Pacific | $ 4652.12 Million | $ 6164.41 Million | $ 10806 Million | 7.268% |
| China | $ 1563.11 Million | $ 2132.89 Million | $ 3879.34 Million | 7.764% |
| Japan | $ 967.64 Million | $ 1220.55 Million | $ 1945.07 Million | 5.998% |
| South Korea | $ 390.78 Million | $ 505.48 Million | $ 842.87 Million | 6.6% |
| India | $ 530.34 Million | $ 739.73 Million | $ 1426.39 Million | 8.554% |
| Australia | $ 372.17 Million | $ 474.66 Million | $ 788.84 Million | 6.555% |
| Singapore | $ 125.61 Million | $ 154.3 Million | $ 248.54 Million | 6.14% |
| Taiwan | $ 139.56 Million | $ 172.6 Million | $ 280.96 Million | 6.279% |
| South East Asia | $ 455.91 Million | $ 610.28 Million | $ 1080.6 Million | 7.403% |
| Rest of APAC | $ 107 Million | $ 153.93 Million | $ 313.37 Million | 9.293% |
| South America | $ 1108.68 Million | $ 1412.11 Million | $ 2288.32 Million | 6.22% |
| Brazil | $ 462.32 Million | $ 605.8 Million | $ 1029.74 Million | 6.856% |
| Argentina | $ 191.8 Million | $ 244.3 Million | $ 393.59 Million | 6.143% |
| Colombia | $ 158.54 Million | $ 203.34 Million | $ 338.67 Million | 6.584% |
| Peru | $ 102 Million | $ 125.68 Million | $ 189.93 Million | 5.297% |
| Chile | $ 104.22 Million | $ 128.5 Million | $ 196.8 Million | 5.472% |
| Rest of South America | $ 89.8 Million | $ 104.5 Million | $ 139.59 Million | 3.686% |
| Middle East | $ 826.08 Million | $ 1031.93 Million | $ 1695.05 Million | 6.4% |
| Saudi Arabia | $ 319.69 Million | $ 403.48 Million | $ 674.63 Million | 6.636% |
| Turkey | $ 159.43 Million | $ 201.23 Million | $ 339.01 Million | 6.737% |
| UAE | $ 128.21 Million | $ 156.85 Million | $ 245.78 Million | 5.775% |
| Egypt | $ 128.04 Million | $ 158.92 Million | $ 250.87 Million | 5.873% |
| Qatar | $ 47.09 Million | $ 61.92 Million | $ 111.87 Million | 7.675% |
| Rest of Middle East | $ 43.62 Million | $ 49.53 Million | $ 72.89 Million | 4.947% |
| Africa | $ 652.17 Million | $ 814.68 Million | $ 1228.91 Million | 5.273% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | $ 262.82 Million | $ 320.98 Million | $ 462.07 Million | 4.659% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
Leading Players (Source: https://www.inven.ai/company-lists/top-22-respiratory-device-companies)
The leading companies in the global medical device market maintain their dominant positions due to a strategic blend of technological innovation, global reach, diversified product portfolios, and acquisitions. Key players include:
lead the global respiratory devices market due to their strong innovation pipelines, global reach, and comprehensive product portfolios. Philips offers advanced ventilators and oxygen concentrators, catering to both hospital and homecare settings. (Source: https://www.philips.co.in/healthcare/solutions/sleep-and-respiratory-care/oxygen) Medtronic dominates with critical care ventilators and invasive/non-invasive solutions. (Source:https://www.medtronic.com/en-us/healthcare-professionals/products/respiratory.html#aq=%40pagetype%3D%22product-model%22&cq=%40products_category%3D%22Respiratory%22%20OR%20%40ontology_isa%3D%22Respiratory%22) ResMed Inc. is a global leader in sleep apnea devices, especially CPAP machines, and leverages digital health platforms to improve patient adherence and remote monitoring. (Source:https://www.resmed.com/en-us/)
Other prominent players such as Fisher & Paykel Healthcare, Drägerwerk, and Masimo bring depth through specialized offerings like humidification systems, respiratory monitoring, and patient safety solutions. Their collective R&D, regulatory compliance, and global logistics capabilities solidify their standing in this fast-evolving market. (Source:https://www.fphcare.com/in/hospital/adult-respiratory/ , https://www.draeger.com/en_in/Safety/Respiratory-Protective-Equipment , https://www.masimo.com/solutions/acute/respiratory/)
Upcoming Players (Source: https://www.labiotech.eu/best-biotech/respiratory-disease-companies/ , https://www.nsmedicaldevices.com/analysis/new-respiratory-medical-technologies/?cf-view)
There are several emerging players in the Respiratory devices market that are gaining traction due to their focus on next-generation technologies, novel therapeutic approaches, and addressing unmet clinical needs. Key upcoming players are (Source:https://www.nsmedicaldevices.com/analysis/new-respiratory-medical-technologies/?cf-view&cf-closed):
Emerging players like X-COR Therapeutics and Circadia Health are gaining traction by addressing critical unmet needs with breakthrough innovation. (https://xcortherapeutics.com/) Meanwhile, Aerin Medical offers non-invasive treatments for nasal airway obstruction that enhance breathing without surgery, indirectly supporting respiratory wellness. (https://vivaer.com/) Additionally, Hospitech Respiration is innovating airway management through its AnapnoGuard system, which prevents ventilator-associated complications, making it valuable in critical care units. (https://www.hospitech.co.il/ag100s)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Resmed | ••• | ••• | ••• | ••• |
| Philips Healthcare | ••• | ••• | ••• | ••• |
| Medtronic | ••• | ••• | ••• | ••• |
| Carefusion | ••• | ••• | ••• | ••• |
| GE Healthcare | ••• | ••• | ••• | ••• |
| Teijin Pharma | ••• | ••• | ••• | ••• |
| Drager Medical | ••• | ••• | ••• | ••• |
| Fisher & Paykel | ••• | ••• | ••• | ••• |
| MEKICS | ••• | ••• | ••• | ••• |
| Weinmann | ••• | ••• | ••• | ••• |
| Air Liquide | ••• | ••• | ••• | ••• |
| Maquet | ••• | ••• | ••• | ••• |
| SLE Ltd | ••• | ••• | ••• | ••• |
| Hamilton Medical | ••• | ••• | ••• | ••• |
| eVent Medical | ••• | ••• | ••• | ••• |
| DeVilbiss | ••• | ••• | ••• | ••• |
| Apex Medical | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →The global respiratory devices market is on a significant growth trajectory, projected to expand from $21,738.9 million in 2021 to $42,376.3 million by 2033, at a robust CAGR of 5.72%. This expansion is primarily fueled by the increasing prevalence of chronic respiratory diseases such as COPD and asthma, a growing global geriatric population more susceptible to such conditions, and the rising levels of air pollution worldwide. Technological advancements are revolutionizing the market, leading to the development of more portable, efficient, and user-friendly devices. The trend towards home-based healthcare, accelerated by the recent global pandemic, has further boosted the demand for devices like portable oxygen concentrators, CPAP machines, and nebulizers. While North America currently dominates the market, the Asia Pacific region is expected to witness the fastest growth due to rising healthcare expenditure and awareness.
To capitalize on the evolving market landscape, manufacturers should prioritize investment in R&D to develop innovative, portable, and IoT-enabled devices that cater to the growing home healthcare trend. Expanding market presence in high-growth Asia Pacific countries through strategic partnerships and localized pricing strategies will be crucial for long-term growth. Furthermore, focusing on patient education and simplifying device usability can enhance adherence and brand loyalty. Engaging with regulatory bodies early in the development process and generating robust clinical data can help streamline market access and strengthen reimbursement negotiations.
Respiratory Devices are medical devices that are used to help a patient suffering from breathing problems. These devices are used in the management and treatment of disorders such as COPD (Chronic obstructive pulmonary disease), fibrosis, asthma and acute respiratory distress syndrome. Oxygen concentrators are expected to dominate the global market in terms of revenue share. This is attributed to the, growing incidence of respiratory diseases, rising demand for home oxygen treatment, and rapid growth in the older population.
The 2025 U.S. tariffs on medical imports from countries like China and Germany have increased costs for components critical to respiratory device manufacturing, such as sensors, plastic tubing, and circuit boards. Companies like Philips Respironics and GE HealthCare are now facing higher operational expenses, pushing some to consider regionalizing supply chains. These tariffs may delay product launches and increase end-user prices for home ventilators and CPAP devices. Smaller players with offshore production are particularly vulnerable as there is expected increased cost for offshore manufacturing. (https://www.iqvia.com/-/media/iqvia/pdfs/us/insight-briefs/iqvia-ten-medtech-trends-for-2025-insight-brief.pdf , https://budgetlab.yale.edu/research/where-we-stand-fiscal-economic-and-distributional-effects-all-us-tariffs-enacted-2025-through-april)
As per Cognitive's Research Analyst, Respiratory Devices are products designed for the diagnosis, monitoring, and treatment of respiratory disorders. They play an essential role in improving patient outcomes and quality of life for various respiratory ailments, from diagnosis and monitoring to therapeutic applications.
Looking at the Historical Growth The global market expanded from $21,738.9 million in 2021 to an estimated $28710.21 million in 2026 due to the increasing prevalence of chronic respiratory illnesses, a growing susceptible geriatric demographic, and escalating global air pollution levels. Regionally, North America grew from $8608.6 million in 2021 to $10968.11 million in 2026, while Europe progressed from $5891.24 million to $7665.23 million over the same period.
Currently in 2026, North America holds a commanding 38.21% of the global market, driven by a high incidence of conditions like COPD and sleep apnea, robust healthcare systems with substantial expenditure, and supportive reimbursement frameworks. The therapeutic device segment remains the primary consumer of Respiratory Devices. Additionally Asia Pacific is set to be the fastest-growing region, exhibiting the highest CAGR of 7.268%, fueled by a substantial and underserved patient base suffering from respiratory infections, coupled with rapidly developing medical facilities, and the expanding disposable incomes of the middle class.
The market is witnessing a definitive shift towards home-based healthcare solutions, driven by enabling patients to manage their conditions outside traditional clinical settings and boosting demand for portable, user-friendly devices. Ongoing innovation in digital health technologies, including IoT-enabled platforms, is also leading, focusing on enhancing patient adherence and generating valuable data for improved disease management.
In the future, The global Respiratory Devices market will reach to $42,376.3 million by 2033, expanding at a compound annual growth rate of 5.72% from 2021, primarily driven by the continuing rise in chronic respiratory disease prevalence and an expanding aging population. Ongoing innovation in advancements in connected device technology and remote monitoring and the strong trend towards patient-centric home care options will also contribute significantly.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
★ Reviews
Rate this report
| Type | Invasive, Non invasive |
|---|---|
| Application | Hospitals/Clinics, Household, Other (In army Outer space etc.) |
| Product | Therapeutic Devices, Drug Delivery Devices, Mechanical Ventilators, Continuous Positive Airway Pressure, Resuscitators, Humidifiers, Airway Clearance Devices, Oxygen Concentrators, Consumables & Disposables, Others |
| Indication | Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, Others |
| Conclusion | The global respiratory device market is at a pivotal juncture, shaped by rising chronic respiratory conditions, aging populations, and the growing demand for home-based care. There is a significant shift toward smart, connected devices that enable remote monitoring and early intervention, driven by AI, IoT, and wearable tech integration. Post-pandemic resilience has also spurred regulatory agility and faster adoption cycles. Companies investing in user-friendly designs, digital health ecosystems, and value-based care models are best positioned to lead. Emerging markets, with unmet needs and rising healthcare access, offer untapped growth, making localization strategies and cost-effective innovation critical for sustained success. |
| List of Competitors | Resmed, Philips Healthcare, Medtronic, Carefusion, GE Healthcare, Teijin Pharma, Drager Medical, Fisher & Paykel, MEKICS, Weinmann, Air Liquide, Maquet, SLE Ltd, Hamilton Medical, eVent Medical, DeVilbiss, Apex Medical |
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Respiratory Devices Market Analysis Market analysis.
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Explore the emerging key innovators in the global respiratory devices market. From AI-powered monitoring to non-invasive care, discover how technology is driving patient-centered, proactive respiratory healthcare.
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Respiratory Devices Market Analysis market.
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the respiratory devices market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
